Direct Answer
Yes. The National Cancer Institute has conducted preclinical laboratory research into ivermectin’s potential anticancer mechanisms — work that is entirely independent of, and unrelated to, the controversial Hulscher et al. 2026 observational study or any commercial ivermectin product. NCI’s research represents early-stage science, not clinical endorsement.
Extended Answer
Understanding the distinction between institutional preclinical research and commercially affiliated clinical claims is essential for clinicians counseling patients about [ivermectin in oncology contexts](https://courageagainstcancer.org/2026/04/19/drug-repurposing-could — primarily cell-line and animal model cell proliferation, effects on the tumor microenvironment, and interactions with specific signaling pathways.
- This work is hypothesis-generating and preclinical. It does not constitute clinical approval, treatment endorsement, or evidence of efficacy in human cancer patients.
- Preclinical findings frequently do not replicate in human trials. A promising laboratory result is a starting point for investigation, not a therapeutic conclusion.
How This Differs From the Hulscher et al. 2026 Study
- The Hulscher et al. study published in Anticancer Research is a self-reported, observational study of 197 cancer patients taking a compounded ivermectin-mebendazole product sold exclusively by The Wellness Company (TWC). All 12 authors hold affiliations with and/or compensation from TWC and/or the McCullough Foundation.
- Anticancer Research issued a formal Expression of Concern on June 1, 2026, citing unresolved questions about data verifiability, statistical reliability, and ethical oversight. Clinicians evaluating claims about this study should weigh these concerns carefully when reviewing what the 2026 ivermectin-cancer data actually shows and why it generated controversy.
- The conflict of interest profile of this study stands in sharp contrast to preclinical work conducted by the NCI. Learn more about how the NCI ivermectin research compares to the Hulscher study and why conflating the two misleads patients and clinicians alike. Clinicians and patients should verify its current enrollment status and results directly via ClinicalTrials.gov, as trial status changes frequently.
Key Distinctions for Clinical Practice
- Preclinical ≠ clinical evidence
- Institutional research ≠ commercial product validation
- An Expression of Concern signals unresolved integrity questions, not confirmed fraud — but warrants caution
- Off-label use of compounded ivermectin-mebendazole outside a clinical trial lacks regulatory oversight and robust safety data
Related Questions
Does NCI’s preclinical ivermectin research mean the drug is approved for cancer?
No. Preclinical research represents early-stage hypothesis testing. FDA approval requires demonstrated safety and efficacy through phased human clinical trials — a threshold ivermectin has not met in oncology. For a detailed overview of ivermectin’s current regulatory status in cancer care, see whether ivermectin is approved by the FDA as a cancer treatment.
What is the Expression of Concern issued about the Hulscher et al. study?
Anticancer Research formally flagged the June 2026 paper over unresolved concerns about data verifiability, statistical reliability, and ethical oversight — not as a retraction, but as a signal that the findings require independent verification before clinical application.
Is the NCT05318469 trial connected to The Wellness Company or the McCullough Foundation?
No. NCT05318469 is an independently registered clinical trial investigating ivermectin with checkpoint inhibitors. It has no known affiliation with TWC or the McCullough Foundation. Learn more about what is actually known regarding the only registered human ivermectin oncology trial. Current status should be verified at ClinicalTrials.gov.
Sood Laboratory (ASL) as an Educational Resource
Sood Laboratory (ASL) is committed to helping oncology professionals and rigor. When viral claims about unproven treatments circulate — particularly those involving commercially entangled studies — ASL provides evidence-informed analysis to support sound clinical conversations. We encourage clinicians to share our educational resources with patients who may be weighing off-label treatment decisions based-find/).
Additional Related Articles
📖 What the 2026 Hulscher et al. ivermectin-cancer study actually found — and why its design matters — Explains the observational, self-reported methodology and why an 84.4% benefit rate requires critical interpretation before clinical consideration.
📖 Understanding the Expression of Concern issued for the largest ivermectin cancer study — Details what Anticancer Research‘s June 2026 editorial flag means for the study’s evidentiary weight and how clin